DalsnaFinance Account

Enliven Therapeutics Inc $ELVN

Health Care

Russell 2000 California

Create a scorecard

$41.93

+0.11 (+0.26%)

As of Oct 22, 2026, 9:33 PM EDT · cached

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 1, 2026, the first target we tracked for ELVN.

Enliven Therapeutics Inc (ELVN) is trading up at $41.93 (+0.26%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Analyst price targets on ELVN

Current price targets from 3 firms average $74.3, median $75, ranging from $70 to $78 — the average is 77% above the current $41.9. Each is tracked to its date and scored the same way a member's call is.

Guggenheim $40.6 → $78 by Oct 2027 Buy Oct 8, 2026 via Investing.com · Guggenheim's track record
Morgan Stanley $47 → $70 by Oct 2027 Overweight Oct 2, 2026 via Investing.com · Morgan Stanley's track record
JPMorgan $46.2 → $75 by Oct 2027 Overweight Oct 1, 2026 via Investing.com · JPMorgan's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Enliven Therapeutics Inc net income history (FY2019–FY2025)

Net income

Enliven Therapeutics Inc annual financial statements
	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Operating income	−$24.1M	−$41.7M	−$51.4M	−$38.8M	−$83.5M	−$104.6M	−$119.7M
Net income	−$23.5M	−$41.4M	−$51.4M	−$37.7M	−$71.6M	−$89.0M	−$103.7M
EPS (diluted)	−$1202.40	−$127.08	−$14.22	−$12.05	−$2.01	−$1.89	−$1.83
Balance sheet
Cash and equivalents	$4.94M	$47.7M	$48.3M	$75.5M	$100.1M	$124.1M	$98.9M
Total assets	$33.3M	$90.8M	$93.6M	$83.3M	$271.9M	$325.8M	$476.2M
Total liabilities	$4.38M	$6.41M	$7.62M	$10.4M	$26.0M	$15.9M	$16.6M
Shareholders' equity	−$48.8M	$84.4M	−$42.9M	−$76.8M	$245.9M	$309.8M	$459.6M
Cash flow
Operating cash flow	−$21.9M	−$37.4M	−$46.8M	−$32.1M	−$61.3M	−$73.2M	−$70.3M
Capital expenditure	$140.0K	$18.0K	$12.0K	$612.0K	$149.0K	$44.0K	$158.0K
Free cash flow	−$22.0M	−$37.4M	−$46.8M	−$32.7M	−$61.4M	−$73.2M	−$70.5M

Net income

Enliven Therapeutics Inc quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Operating income	−$27.1M	−$26.9M	−$31.7M	−$28.6M	−$25.1M	−$34.3M	−$27.8M	−$37.2M
Net income	−$23.2M	−$23.2M	−$28.5M	−$25.3M	−$20.1M	−$29.7M	−$23.6M	−$32.5M
EPS (diluted)	−$0.48	−$0.46	−$0.57	−$0.49	−$0.32	−$0.45	−$0.38	−$0.49
Balance sheet
Cash and equivalents	$100.6M	$124.1M	$101.7M	$119.4M	$101.7M	$98.9M	$132.2M	$135.5M
Total assets	$305.4M	$325.8M	$302.6M	$503.9M	$490.9M	$476.2M	$464.9M	$910.2M
Total liabilities	$17.0M	$15.9M	$14.3M	$15.4M	$14.8M	$16.6M	$11.5M	$15.1M
Shareholders' equity	$288.4M	$309.8M	$288.3M	$488.5M	$476.1M	$459.6M	$453.4M	$895.1M
Cash flow
Operating cash flow	−$12.2M	−$17.2M	−$24.1M	−$17.1M	−$13.3M	−$15.8M	−$19.3M	−$18.5M
Capital expenditure	$22.0K	$0	$20.0K	$139.0K	−$1.00K	$0	$0	$99.0K
Free cash flow	−$12.2M	−$17.2M	−$24.1M	−$17.2M	−$13.3M	−$15.8M	−$19.3M	−$18.6M

From Enliven Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →